{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-003852","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.876031+00:00","generated_at":"2026-05-21T07:21:45.291650+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VolitionRx Q1 revenue $0.25M (+44% YoY); first commercial revenue from CE-marked Nu.Q NETs in Europe","bullets":["Revenue of ~$0.25M in Q1 2025, up 44% from Q1 2024; first revenue from regulated CE-marked Nu.Q NETs automated product.","Net cash used in ops averaged $1.4M/month, down ~50% vs Q1 2024; cash balance $2.6M at March 31, 2025.","Post-quarter closed $6.25M convertible loan note (24-month, 6-month repayment holiday).","Confidential licensing discussions with >10 companies; combined market cap of seven >$600B.","Goal to be cash neutral on full-year 2025 basis via licensing receipts and cost reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-003852","json":"https://secwatch.observer/filing/0001477932-25-003852.json","markdown":"https://secwatch.observer/filing/0001477932-25-003852.md","text":"https://secwatch.observer/filing/0001477932-25-003852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793225003852/0001477932-25-003852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793225003852/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T07:21:45.291650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}